Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Dose Escalation Study of CD19/CD22 Bicistronic CAR T Cells in B Cell Malignancies
NCT05442515Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2022
- Primary completion
- Jul 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of CD19 + CD22 bispecific CAR T-cell in acute lymphoblastic leukemia (ALL) and B cell lymphoma (9 arms), sponsored by National Cancer Institute. Primary endpoints: Safety and Efficacy. Started Dec 2022; status: recruiting.
02
Drugs
CD19 + CD22 bispecific CAR T-cell
03
Conditions
acute lymphoblastic leukemia (ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT05442515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05442515.